Navigation Links
Hill-Rom Receives FDA 510(k) Clearance to Market MetaNeb 4.0 Airway Clearance System
Date:5/6/2013

BATESVILLE, Ind., May 6, 2013 /PRNewswire/ -- Hill-Rom Holdings, Inc. (NYSE: HRC), a global leader in healthcare technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration  to market the MetaNeb® 4.0 System, the company's latest advancement in airway clearance technology for enhanced patient care in the hospital.  Delivering therapy through airway oscillation (Continuous High Frequency Oscillation) and continuous pressure (Continuous Positive Expiratory Pressure), the MetaNeb 4.0 System helps enhance normal mucus clearance from the lungs, delivers lung expansion therapy, and assists in the treatment and prevention of pulmonary atelectasis, a complete or partial collapse of the lung. 

(Logo: http://photos.prnewswire.com/prnh/20130123/DE47178LOGO )

The system also has the ability to provide supplemental oxygen when used with compressed oxygen. The next-generation MetaNeb 4.0 System improves therapy performance, enhances ease of use when used with mechanical ventilation, and enhances therapy delivery.

"The design enhancements to the MetaNeb System represent another great example of Hill-Rom's dedication to improving outcomes for patients and their caregivers," said Greg Pritchard , Senior Vice President, Surgical and Respiratory Care, for Hill-Rom.  "Together with The Vest® Airway Clearance System, our Respiratory Care portfolio now offers complementary innovative solutions for patients with respiratory disorders."

Patients who may benefit from the MetaNeb 4.0 System, which will begin shipping in June, include those with one or more of the following disease states:

  • Bronchiolitis
  • Cystic Fibrosis
  • Asthma
  • Chronic Bronchitis
  • Neuromuscular Disorders
  • Emphysema
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Patients Needing Post-Operative Airway Management
  • Patients Needing Emergency Room Airway Management

ABOUT HILL-ROM HOLDINGS, INC.
Hill-Rom is a leading worldwide manufacturer and provider of medical technologies and related services for the health care industry, including patient support systems, safe mobility and handling solutions, non-invasive therapeutic products for a variety of acute and chronic medical conditions, medical equipment rentals, surgical products, and information technology solutions.  Hill-Rom's comprehensive product and service offerings are used by health care providers across the health care continuum and around the world in hospitals, extended care facilities and home care settings to enhance the safety and quality of patient care.

Hill-Rom...enhancing outcomes for patients and their caregivers.

www.hill-rom.com

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements in this press release contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding the Company's future plans, objectives, beliefs, expectations, representations and projections.  The Company has tried, wherever possible, to identify these forward-looking statements using words such as "intend," "anticipate," "believe," "plan," "encourage," "expect," "may," "goal," "become," "pursue," "estimate," "strategy," "will," "projection," "forecast," "continue," "accelerate," "promise," "increase," "higher," "lower," "reduce," "improve," "expand," "progress," "potential" or the negative of those terms or other variations of them or by comparable terminology.  The absence of such terms, however, does not mean that the statement is not forward-looking.  It is important to note that forward-looking statements are not guarantees of future performance, and the Company's actual results could differ materially from those set forth in any forward-looking statements.  Factors that could cause actual results to differ from forward-looking statements include but are not limited to: the Company's dependence on its relationships with several large group purchasing organizations, whether the Company's new products are successful in the marketplace, impacts of healthcare reform, compliance with federal healthcare programs, collections of accounts receivable, compliance with FDA regulations, potential exposure to product liability or other claims, failure of the Company's announced or future strategic initiatives and restructuring and realignment activities to achieve expected growth, efficiencies or cost reductions, failure of the Company to execute its acquisition and business alliance strategy through the consummation and successful integration of acquisitions or entry into joint ventures or other business alliances, increased costs or unavailability of raw materials, adverse changes in global economic conditions or disruptions of credit markets, labor disruptions, the ability to retain executive officers and other key personnel, and certain tax-related matters.  For a more in depth discussion of these and other factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in the Company's previously filed most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.  The Company assumes no obligation to update or revise any forward-looking statements.

 


'/>"/>
SOURCE Hill-Rom Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hill-Rom Reports Fiscal Second Quarter Adjusted Earnings Per Share In Line With Expectations; Provides Third Quarter And Updated Full-Year Financial Outlook
2. Hill-Rom Holdings, Inc. to Host Investor Conference May 7
3. Hill-Rom Holdings, Inc. Hosts Fiscal 2013 Second Quarter Earnings Conference Call and Webcast
4. Hill-Rom Elects William H. Kucheman to its Board of Directors
5. Hill-Rom Announces Second Quarter 2013 Dividend
6. Hill-Rom to Participate in the 2013 Citi Global Healthcare Conference
7. Hill-Rom Reports Fiscal First Quarter Results; Updates 2013 Financial Outlook For R&D Tax Credit Reinstatement
8. Hill-Rom Announces First Quarter 2013 Dividend
9. Hill-Rom to Participate in the 24th Annual Piper Jaffray Healthcare Conference
10. Hill-Rom Announces Fourth Quarter 2012 Dividend
11. Hill-Rom to Participate in the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):